Presented for attendees of The Liver Meeting® 2025. This event/function is provided by Med Learning Group and supported by Novo Nordisk. This is not an official event/function of the American Association for the Study of Liver Diseases.
Friday, November 7, 2025
12:00 PM – 12:30 PM EST: Registration/Lunch
12:30 PM – 2:00 PM EST: Symposium
Walter E. Washington Convention Center
801 Allen Y. Lew Place NW
Washington, DC 20001
Meeting Room: Room 147
PROGRAM CHAIRS & PRESENTING FACULTY
 |
Naim Alkhouri, MD, FAASLD, DABOM Chief Academic Officer at Summit Clinical Research Chief Medical Officer Director, Fatty Liver Program Chief of Transplant Hepatology Westlake, OH |
 |
Sonal Kumar, MD, MPH Assistant Professor of Medicine Director of Clinical Hepatology Weill Cornell Medical College New York, NY |
PROGRAM OVERVIEW
This interactive live symposium is designed to enhance the knowledge and clinical competence of hepatologists and gastroenterologists in the diagnosis, risk stratification, and treatment of metabolic dysfunction-associated steatohepatitis (MASH). Expert-led sessions will provide the latest insights into noninvasive diagnostic tools (NITs), guideline-driven staging, and treatment. The faculty will discuss current and emerging pharmacologic therapies, evidence-based lifestyle interventions, and the management of comorbidities that influence disease progression and overall patient outcomes. Throughout the program, interactive case-based breakout discussions and audience polling will engage learners in applying concepts to clinical scenarios, addressing real-world challenges in the diagnosis and proactive management of MASH.
LEARNING OBJECTIVES:
- Implement AASLD guideline recommendations to enable early MASH diagnosis, including MASH screening for at-risk individuals and the use of non-invasive diagnostic techniques, such as biomarker- and imaging-based testing
- Incorporate AASLD guideline recommendations for the medical management of MASH, including lifestyle modification and pharmacologic management recommendations, into clinical practice
- Analyze the efficacy and safety data from MASH clinical trials evaluating treatment with resmetirom or GLP-1 RAs for patients with MASH to inform the development of patient-centric, evidence-based treatment plans
TARGET AUDIENCE
This activity is intended for hepatologists and gastroenterologists.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.50 ANCC contact hours.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.5 knowledge-based continuing pharmacy education (CPE) contact hours.
NOTE to pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at [email protected]
